Rabies - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Rabies - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Rabies - Pipeline Review, H2 2014', provides an overview of the Rabies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rabies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rabies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rabies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rabies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rabies Overview 9
Therapeutics Development 10
Pipeline Products for Rabies - Overview 10
Pipeline Products for Rabies - Comparative Analysis 11
Rabies - Therapeutics under Development by Companies 12
Rabies - Therapeutics under Investigation by Universities/Institutes 14
Rabies - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Rabies - Products under Development by Companies 18
Rabies - Products under Investigation by Universities/Institutes 19
Rabies - Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co., Ltd 20
Celltrion, Inc. 21
Crucell N.V. 22
CureVac GmbH 23
Humabs BioMed SA 24
Kaketsuken K.K. 25
Kamada Ltd. 26
Medicago Inc. 27
Molecular Targeting Technologies, Inc. 28
NanoViricides, Inc. 29
Novavax, Inc. 30
PaxVax 31
Sanofi Pasteur SA 32
Serum Institute of India Limited 33
Sinovac Biotech Ltd. 34
Trellis Bioscience, Inc. 35
VBI Vaccines 36
Zydus Cadila Healthcare Limited 37
Rabies - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
CL-184 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CTP-19 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CV-7201 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CV-8102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ebola and marburg + rabies vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
human rabies vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KD-357 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibodies for Rabies - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibody for Rabies - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PAV-866 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RabiCide-I - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
rabies (virus like particles) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rabies immune globulin (human) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rabies vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rabies vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rabies vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rabies vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rabies vaccine [MRC-5] - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Rabies VRVg - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Rabimabs Vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SII RMab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SO-57 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SOJB - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Rabies - Recent Pipeline Updates 74
Rabies - Dormant Projects 76
Rabies - Product Development Milestones 77
Featured News & Press Releases 77
Jun 24, 2009: Crucell Announces Positive Results Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In Philippines 77
Jun 24, 2009: Crucell Presents Positive Phase II Study Results Of Rabies Monoclonal Antibody Combination At RITA Conference 77
Oct 01, 2008: Crucell Announces Positive Results Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In US 78
May 13, 2008: Crucell Initiates Phase II Clinical Study For Rabies Monoclonal Antibody Combination In The Philippines 79
Mar 31, 2008: Crucell Announces Start Of Phase II Clinical Study Rabies Monoclonal Antibody Combination In US 79
Jan 03, 2008: Crucell Enters Agreement With Sanofi Pasteur For Next-generation Biologicals Against Rabies 80
Nov 30, 2007: Crucell Presents Positive Results Of Indian Phase I Rabies Antibody Cocktail Study 80
Apr 04, 2007: Crucell Announces Start Of Rabies Phase I Antibody Cocktail Clinical Study In India 81
Oct 13, 2006: Crucell Announces Start Of Rabies Antibody Product Clinical Trial 81
Jun 14, 2005: Crucell Announces Clinical Development Of Human Monoclonal Antibody Combination Against Rabies 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products under Development for Rabies, H2 2014 10
Number of Products under Development for Rabies - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 20
Rabies - Pipeline by Celltrion, Inc., H2 2014 21
Rabies - Pipeline by Crucell N.V., H2 2014 22
Rabies - Pipeline by CureVac GmbH, H2 2014 23
Rabies - Pipeline by Humabs BioMed SA, H2 2014 24
Rabies - Pipeline by Kaketsuken K.K., H2 2014 25
Rabies - Pipeline by Kamada Ltd., H2 2014 26
Rabies - Pipeline by Medicago Inc., H2 2014 27
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H2 2014 28
Rabies - Pipeline by NanoViricides, Inc., H2 2014 29
Rabies - Pipeline by Novavax, Inc., H2 2014 30
Rabies - Pipeline by PaxVax, H2 2014 31
Rabies - Pipeline by Sanofi Pasteur SA, H2 2014 32
Rabies - Pipeline by Serum Institute of India Limited, H2 2014 33
Rabies - Pipeline by Sinovac Biotech Ltd., H2 2014 34
Rabies - Pipeline by Trellis Bioscience, Inc., H2 2014 35
Rabies - Pipeline by VBI Vaccines, H2 2014 36
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Assessment by Combination Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 41
Number of Products by Stage and Route of Administration, H2 2014 43
Number of Products by Stage and Molecule Type, H2 2014 45
Rabies Therapeutics - Recent Pipeline Updates, H2 2014 74
Rabies - Dormant Projects, H2 2014 76